FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751595696> ?p ?o ?g. }

• W2751595696 abstract "Background Anabasum (JBT-101) is a synthetic, oral, non-immunosuppressive, preferential CB2 agonist. It inhibits onset and activates resolution of innate immune responses in animal models of systemic sclerosis (SSc). Objectives Evaluate safety and efficacy of anabasum in SSc Methods A double-blind, randomized, placebo (PBO)-controlled Phase 2 trial dosed 42 diffuse cutaneous SSc subjects with disease duration ≤6 years on stable medication including immunosuppressive drugs. Subjects received anabasum 5 mg QD, 20 mg QD, or 20 mg BID on Days 1–28, then 20 mg BID on Days 29–84, or PBO on Days 1–84. Subjects were followed off study drug on Days 85–113. The primary safety outcome was treatment-emergent adverse events (TEAEs). The primary efficacy outcome was improvement in ACR Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, combined anabasum group vs PBO, Days 29–113 (end of Weeks 4–16). The five domains of the ACR CRISS are the modified Rodnan skin score, HAQ-DI, patient and physician global assessments, and FVC % predicted. Results Of 42 dosed subjects, 27 (64%) received anabasum and 15 (36%) received PBO. Three anabasum subjects withdrew: 1 (3.7%) for a TEAE of moderate dizziness; 1 withdrew consent; and 1 by physician decision. One PBO subject withdrew consent. Baseline demographic and CRISS domain scores were similar except slightly more anabasum subjects used background immunosuppressive drugs (93% versus 80%, anabasum vs PBO). Seventeen (63%) anabasum subjects had 66 TEAEs, and 9 (60%) PBO subjects had 35 TEAEs. There were no serious, severe, or unexpected TEAEs related to anabasum. Severity and relationship of TEAEs to study drug were similar in both groups. The most frequent TEAEs by MedDRA system (% anabasum vs % PBO) were: nervous system (37% vs 27%); general disorders (30% vs 7%); gastrointestinal (22% vs 20%); infections (22% vs 20%); musculoskeletal (22% vs 13%); and investigations (0% vs 20%). The most frequent TEAEs in anabasum subjects were dizziness (22%) and fatigue (19%) which were usually mild. Anabasum subjects had greater improvement in ACR CRISS scores than PBO subjects (mixed model repeated measures analysis, p=0.044, 1-sided). The median ACR CRISS scores at the end of Weeks 4, 8, 12, and 16 (anabasum vs PBO) were 3.0% vs 1.0%, 19.0% vs 1.0%, 27.5% vs 1.0%, and 33.0% vs 1.0%, respectively. Among anabasum subjects, ∼50% had ACR CRISS ≥20% after 8 weeks of dosing. The individual domains of the ACR CRISS score showed greater improvement, improvement that reached minimal important differences in several domains, and less worsening in anabasum vs PBO groups. Anabasum subjects had greater improvement in SSc skin symptoms and itch. Plasma metabolipidomic profiles showed anabasum, not PBO, shifted lipid mediator production to increase pro-resolving vs pro-inflammatory lipid mediators. Conclusions Anabasum provided significant and medically meaningful efficacy in SSc as assessed by the ACR CRISS score and its individual domains and had acceptable safety and tolerability in this Phase 2 trial. These data support continued clinical development of anabasum for the treatment of SSc. Disclosure of Interest R. Spiera: None declared, L. Hummers: None declared, L. Chung: None declared, T. Frech: None declared, R. Domsic: None declared, D. Furst: None declared, J. Gordon: None declared, M. Mayes: None declared, R. Simms: None declared, S. Constantine Employee of: Corbus Pharmaceuticals, Inc., B. White Employee of: Corbus Pharmaceuticals, Inc." @default.
• W2751595696 created "2017-09-15" @default.
• W2751595696 creator A5004355994 @default.
• W2751595696 creator A5009211703 @default.
• W2751595696 creator A5011224556 @default.
• W2751595696 creator A5014590777 @default.
• W2751595696 creator A5026240805 @default.
• W2751595696 creator A5052078671 @default.
• W2751595696 creator A5067962806 @default.
• W2751595696 creator A5069078321 @default.
• W2751595696 creator A5077574387 @default.
• W2751595696 creator A5083244531 @default.
• W2751595696 creator A5089758720 @default.
• W2751595696 date "2017-06-01" @default.
• W2751595696 modified "2023-09-23" @default.
• W2751595696 title "OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis" @default.
• W2751595696 doi "https://doi.org/10.1136/annrheumdis-2017-eular.2712" @default.
• W2751595696 hasPublicationYear "2017" @default.
• W2751595696 type Work @default.
• W2751595696 sameAs 2751595696 @default.
• W2751595696 citedByCount "6" @default.
• W2751595696 countsByYear W27515956962018 @default.
• W2751595696 countsByYear W27515956962019 @default.
• W2751595696 countsByYear W27515956962020 @default.
• W2751595696 countsByYear W27515956962021 @default.
• W2751595696 countsByYear W27515956962022 @default.
• W2751595696 crossrefType "proceedings-article" @default.
• W2751595696 hasAuthorship W2751595696A5004355994 @default.
• W2751595696 hasAuthorship W2751595696A5009211703 @default.
• W2751595696 hasAuthorship W2751595696A5011224556 @default.
• W2751595696 hasAuthorship W2751595696A5014590777 @default.
• W2751595696 hasAuthorship W2751595696A5026240805 @default.
• W2751595696 hasAuthorship W2751595696A5052078671 @default.
• W2751595696 hasAuthorship W2751595696A5067962806 @default.
• W2751595696 hasAuthorship W2751595696A5069078321 @default.
• W2751595696 hasAuthorship W2751595696A5077574387 @default.
• W2751595696 hasAuthorship W2751595696A5083244531 @default.
• W2751595696 hasAuthorship W2751595696A5089758720 @default.
• W2751595696 hasBestOaLocation W27515956961 @default.
• W2751595696 hasConcept C126322002 @default.
• W2751595696 hasConcept C141071460 @default.
• W2751595696 hasConcept C142724271 @default.
• W2751595696 hasConcept C197934379 @default.
• W2751595696 hasConcept C203092338 @default.
• W2751595696 hasConcept C204787440 @default.
• W2751595696 hasConcept C27081682 @default.
• W2751595696 hasConcept C2778375690 @default.
• W2751595696 hasConcept C2780580376 @default.
• W2751595696 hasConcept C2910384678 @default.
• W2751595696 hasConcept C512399662 @default.
• W2751595696 hasConcept C535046627 @default.
• W2751595696 hasConcept C71924100 @default.
• W2751595696 hasConcept C90924648 @default.
• W2751595696 hasConceptScore W2751595696C126322002 @default.
• W2751595696 hasConceptScore W2751595696C141071460 @default.
• W2751595696 hasConceptScore W2751595696C142724271 @default.
• W2751595696 hasConceptScore W2751595696C197934379 @default.
• W2751595696 hasConceptScore W2751595696C203092338 @default.
• W2751595696 hasConceptScore W2751595696C204787440 @default.
• W2751595696 hasConceptScore W2751595696C27081682 @default.
• W2751595696 hasConceptScore W2751595696C2778375690 @default.
• W2751595696 hasConceptScore W2751595696C2780580376 @default.
• W2751595696 hasConceptScore W2751595696C2910384678 @default.
• W2751595696 hasConceptScore W2751595696C512399662 @default.
• W2751595696 hasConceptScore W2751595696C535046627 @default.
• W2751595696 hasConceptScore W2751595696C71924100 @default.
• W2751595696 hasConceptScore W2751595696C90924648 @default.
• W2751595696 hasLocation W27515956961 @default.
• W2751595696 hasOpenAccess W2751595696 @default.
• W2751595696 hasPrimaryLocation W27515956961 @default.
• W2751595696 hasRelatedWork W146570412 @default.
• W2751595696 hasRelatedWork W1605008465 @default.
• W2751595696 hasRelatedWork W1993929020 @default.
• W2751595696 hasRelatedWork W2010169076 @default.
• W2751595696 hasRelatedWork W2042502927 @default.
• W2751595696 hasRelatedWork W2601555940 @default.
• W2751595696 hasRelatedWork W2792615508 @default.
• W2751595696 hasRelatedWork W2793158975 @default.
• W2751595696 hasRelatedWork W2805067797 @default.
• W2751595696 hasRelatedWork W2889874679 @default.
• W2751595696 hasRelatedWork W2909263993 @default.
• W2751595696 hasRelatedWork W2955874948 @default.
• W2751595696 hasRelatedWork W3006073208 @default.
• W2751595696 hasRelatedWork W3008600838 @default.
• W2751595696 hasRelatedWork W3012737675 @default.
• W2751595696 hasRelatedWork W3016590390 @default.
• W2751595696 hasRelatedWork W3037559311 @default.
• W2751595696 hasRelatedWork W3085166796 @default.
• W2751595696 hasRelatedWork W3115347313 @default.
• W2751595696 hasRelatedWork W3169295303 @default.
• W2751595696 isParatext "false" @default.
• W2751595696 isRetracted "false" @default.
• W2751595696 magId "2751595696" @default.
• W2751595696 workType "article" @default.